Clovis Oncology Inc. (Nasdaq: CLVS) reported efficacy and safety data from its New Drug Application for rucaparib. The stock price plummeted $6.36 to close at $29.41.
Clovis Oncology reports safety data
October 07, 2016 at 19:57 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.